Intelligence / B2B SaaS / Acquisitions / InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc.
10 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 10 Nov 2026
- Ticker
- INM
- Role
- Completed an acquisition
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 2.01, 2.02, 3.02, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 9.01
- Summary
- On November 6, 2026 (the " Closing Date "), Mentari Therapeutics, Inc., a Nevada corporation (formerly known as InMed Pharmaceuticals Inc.) (prior to the Closing Date, unless context otherwise requires, " InMed " and, after the Closing Date, the " Company "), consummated the previously announced business combination (t
- Location
- Vancouver
- SEC CIK
- 1728328
- Reference
- 0001193125-26-455640
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Find the decision makers at InMed Pharmaceuticals Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
Across AOS Research
Other records for InMed Pharmaceuticals Inc. in our registers.
More in Completed an acquisition
Acquisitions
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.